380605-29-8

Basic information

• Product Name: 1-Cyclopropyl-1,3-dihydroimidazo[4,5-c]pyridine-2-one
• Synonyms: 1-Cyclopropyl-1,3-dihydroimidazo[4,5-c]pyridine-2-one;1-CYCLOPROPYL-1,3-DIHYDROIMIDAZO[4,5-C]PYRIDIN-2-ONE;1-Cyclopropyl-1,3-dihydro-2H-iMidazo[4,5-c]pyridin-2-one
• CAS NO: 380605-29-8
• Molecular Formula: C₉H₉N₃O
• Molecular Weight: 175.18726
• Mol File: 380605-29-8.mol

Chemical Properties

• Appearance: /
• Density: 1.433g/cm³
• Refractive Index: 1.681
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 1-Cyclopropyl-1,3-dihydroimidazo[4,5-c]pyridine-2-one(CAS DataBase Reference)
• NIST Chemistry Reference: 1-Cyclopropyl-1,3-dihydroimidazo[4,5-c]pyridine-2-one(380605-29-8)
• EPA Substance Registry System: 1-Cyclopropyl-1,3-dihydroimidazo[4,5-c]pyridine-2-one(380605-29-8)

Safety Data

• Hazardous Substances Data: 380605-29-8(Hazardous Substances Data)

Usage

Uses

1-Cyclopropyl-1,3-dihydroimidazo[4,5-c]pyridine-2-one is used as an inhibitor of human La protein, which plays a crucial role in the regulation of cellular processes. Its anti-viral activity makes it a promising candidate for the development of new antiviral therapies.
Used in Pharmaceutical Industry:
1-Cyclopropyl-1,3-dihydroimidazo[4,5-c]pyridine-2-one is used as a potential therapeutic agent for the treatment of viral infections. Its ability to inhibit the human La protein suggests that it may be effective in disrupting viral replication and reducing the severity of infections.
Additionally, the compound's unique structure and properties may also make it a candidate for further research and development in other areas of pharmaceuticals, such as the development of new drugs for various diseases and conditions. However, more research is needed to fully understand its potential applications and limitations in these areas.

InChI:InChI=1/C9H9N3O/c13-9-11-7-5-10-4-3-8(7)12(9)6-1-2-6/h3-6H,1-2H2,(H,11,13)

Upstream product

• 5435-54-1 4-hydroxy-3-nitropyridine 
• 31872-62-5 4-methoxy-3-nitro-pyridine 

Downstream Products

• 1383451-33-9 4-(5-bromo-2-((1-cyclopropyl-2-oxo-1H-imidazo[4,5-c]pyridin-3(2H)-yl)methyl)-1H-indol-1-yl)butyl 4-methylbenzensulfonate 

Relevant articles and documents

1-PYRAZOLYL, 5-, 6- DISUBSTITUTED INDAZOLE DERIVATIVES AS LRRK2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF

The present invention is directed to substituted certain 1-pyrazolyl, 5-, 6- disubstituted indazole derivatives of Formula (I) and pharmaceutically acceptable salts thereof, wherein R1, R2, and ring A are as defined herein, which are potent inhibitors of LRRK2 kinase and may be useful in the treatment or prevention of diseases in which the LRRK2 kinase is involved, such as Parkinson's Disease and other diseases and disorders described herein. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of diseases, such as Parkinson's disease, in which LRRK-2 kinase is involved.

Targeting human La and its precursor compound of the protein in the preparation of anti-hepatitis b virus use in medicine

The invention belongs to the field of pharmacy and relates to a lead compound of a targeting human La protein and purpose thereof in preparation of a medicament for resisting hepatitis B virus. According to the invention, research on enhancement of HBVRNA stability by the targeting La protein is employed to screen out the lead compound of the targeting human La protein shown as a formula (I), a formula (II) or a formula (III). Tests show that the lead compound has strong antiviral activity and effect of targeting the La protein. The lead compound of the present invention can be further optimized in structure and has good application prospect; and the lead compound and derivatives thereof can be used for preparation of medicament for resisting hepatitis B virus, as well as preparation of medicament targeting the La protein.

QUINAZOLINE BASED RESPIRATORY SYNCYTIAL VIRUS INHIBITORS

Compounds of Formula (I), wherein R1, R2, R3, R4 and n are defined herein, are useful as inhibitors of RSV.

Non-benzimidazole containing inhibitors of respiratory syncytial virus

Several non-benzimidazole containing inhibitors of respiratory syncytial virus are described. Core template modification, analysis of antiviral activity, physicochemistry and optimisation of properties led to the thiazole-imidazole 13, that showed a good potency and pharmacokinetic profile in the rat.

INDOLES AS RESPIRATORY SYNCYTIAL VIRUS ANTIVIRAL AGENTS

Indoles having inhibitory activity on RSV replication and having the formula I the prodrugs, N-oxides, addition salts, quaternary amines, metal complexes and stereochemically isomeric forms thereof; compositions containing these compounds as active ingredient and processes for preparing these compounds and compositions.

IMIDAZOPYRIDINES AS RESPIRATORY SYNCYTIAL VIRUS ANTIVIRAL AGENTS

A compound satisfying formula I, a prodrug, N-oxide, addition salt, quaternary amine, metal complex, or a stereochemically isomeric form thereof; compositions contain these compounds as active ingredient and processes for preparing these compounds and compositions.

INDOLES AS RESPIRATORY SYNCYTIAL VIRUS ANTIVIRAL AGENTS

Indoles having inhibitory activity on RSV replication and having the formula I the prodrugs, N-oxides, addition salts, quaternary amines, metal complexes and stereochemically isomeric forms thereof, compositions containing these compounds as active ingredient and processes for preparing these compounds and compositions.

AZAINDOLES AS RESPIRATORY SYNCYTIAL VIRUS ANTIVIRAL AGENTS

Azaindoles having inhibitory activity on RSV replication and having the formula (I) compositions containing these compounds as active ingredient and processes for preparing these compounds and compositions.

AZABENZIMIDAZOLES AS RESPIRATORY SYNCYTIAL VIRUS ANTIVIRAL AGENTS

A compound satisfying formula I, a prodrug, N-oxide, addition salt, quaternary metal complex, or a stereochemically isomeric form thereof; (formula I) compositions contain these compounds as active ingredient and processes for preparing these compounds and compositions.

Development of an efficient and scalable process of a respiratory syncytial virus inhibitor

An improved process has been developed for compound 1, a respiratory syncytial virus (RSV) inhibitor. This improved process is convergent, safe, efficient, and useful to prepare compound 1 in kilogram quantities.